The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Official Title: Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Study ID: NCT02530320
Brief Summary: This multicenter, open-label, phase II trial aims to assess the safety and efficacy of palbociclib in adult patients with Oligodendroglioma or recurrent oligoastrocytoma anaplastic with the activity of the protein RB preserved.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Hospital Insular de Canarias, Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Son Espases, Palma de Mallorca, Mallorca, Spain
Consorcio Hospitalario Provincial de Castellón, Castello de la Plana, Valencia, Spain
Hospital Clínic de Barcelona, Barcelona, , Spain
ICO Hospitalet, Barcelona, , Spain
Hospital de León, León, , Spain
Hospital 12 de Octubre, Madrid, , Spain
Hospital Ramón y Cajal, Madrid, , Spain
Hospital Regional de Málaga, Málaga, , Spain
Hospital Virgen del Rocio, Sevilla, , Spain
Hospital Universitario y Politécnico La Fe, Valencia, , Spain
Name: Juan Manuel Sepúlveda
Affiliation: H. 12 de Octubre
Role: PRINCIPAL_INVESTIGATOR